GleamWall
中文EN

PMHS Polomar Health Services, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1265521 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11,701.9%
TTM net income YoY-303.9%
TTM EPS YoY-300.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin49.1%
Operating margin-221.0%
Net margin-224.6%
FCF margin—
EBITDA margin-14.8%

Returns

ROE-469.6%
ROA-193.3%
ROIC (approx.)-392.6%
Asset turnover0.86x

Leverage & solvency

Liabilities / assets325.5%
Debt / equity—
Current ratio0.24x
Interest coverage-61.19x

Cash quality & payout

Operating cash flow / net income-0.04x
Accruals ratio-200.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.13M$1.55M$1.06M$632,057$6,163$5,470$4,542$20,870
Cost of revenue$619,340$715,409$707,163$183,294$1,840$1,638$1,360$11,800
Gross profit$514,435$833,873$349,724$448,763$4,323$3,832$3,182$9,070
SG&A expense$474,367$125,165$144,901$9.36M$619,032$556,658$398,836$702,282
Operating income-$467,876$141,701-$391,163-$8.94M-$628,808-$563,333-$415,408-$689,112
Interest expense$45,674$38,225$27,765$46,198$20,967$42,230$41,447$29,677
Net income-$513,550$103,476-$418,928-$8.99M-$649,775-$605,563-$456,855-$718,790
EBITDA-$468,275$151,189-$381,675$53,276-$369,696-$304,220-$156,295-$433,162
EPS (basic)-0.020.00-0.01—-0.02-0.02-0.02—
EPS (diluted)-0.020.00-0.01—-0.02-0.02-0.02—
Weighted avg. shares (diluted)28.38M28.06M28.02M—28.01M27.67M——
Balance sheet
Cash & equivalents$254,779$178,872$87,818$132,150$38,854$4,678$129,331$6,191
Inventory$8,536$30,119$208,981$93,636$158,810$74,395$70,024$68,777
Current assets$673,560$2.36M$2.21M$322,727$197,664$93,054$201,200$76,813
PP&E, net$24,875$24,476$33,964$43,452$52,941$62,429$71,917$81,405
Total assets$886,874$817,739$567,968$390,043$9.27M$9.43M$9.81M$9.95M
Current liabilities$2.79M—$1.76M$1.61M$1.50M$1.04M$1.66M$1.34M
Total liabilities$2.89M$1.87M$1.76M$1.61M$1.50M$1.04M$1.67M$1.35M
Shareholders' equity-$2.84M-$2.35M-$2.39M-$1.97M$7.02M$7.65M$8.14M$8.60M
Shares outstanding28.38M28.28M28.05M28.02M28.02M27.95M27.66M27.66M
Cash flow statement
Operating cash flow$38,314$121,306$34,376$190,021-$352,659-$187,780-$45,577-$314,995
Capital expenditure———————$0
Free cash flow———————-$314,995
Investing cash flow———————$0
Financing cash flow$37,593-$30,252-$78,708-$96,725$386,835$63,127$168,717$304,984
Depreciation & amortization-$399$9,488$9,488$9.00M$259,112$259,113$259,113$255,950
Stock-based compensation———-$12$20,426———
Dividends paid$7,670———————

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.